Aspirus Health introduces first-of-its-kind TriClip heart procedure
Aspirus Health has introduced the TriClip G4 System, the first FDA-approved technology that allows physicians to repair the tricuspid valve without open-heart surgery.
The device, approved by the U.S. Food and Drug Administration on April 4, 2024, offers a groundbreaking, minimally invasive treatment option for patients with tricuspid valve disease, according to an Aspirus Health news release.




